28 January 2019: Promotion of Propecia (finasteride) by The Belgravia Centre
Updated 14 May 2019
© Crown copyright 2019
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-january-2019/28-january-2019-promotion-of-propecia-finasteride-by-the-belgravia-centre
The MHRA became aware of a webpage entitled “Long term safety of Propecia” published on The Belgravia Centre website. We were concerned that some of the information presented was not consistent with the Summary of Product Characteristics (SPC) for Propecia.
The Belgravia Centre confirmed that the page had been removed as it related to a service that they no longer offered. They also carried out a review of all material relating to finasteride to ensure consistency with the relevant SPCs.